NCT05700149Recruiting
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
Summary
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
Inclusion criteria
1. Male or female adults 18 years or older 2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000 3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve 4. Availability of the baseline and follow-up annotations
Exclusion criteria
1\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland, France, Italy, United States, Argentina, Armenia, Canada, Croatia, India, Netherlands, Poland, Portugal, South Korea, Spain, United Kingdom
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)(Other)
- Protocol no.
- IELSG52
- Conditions
- Nodal Marginal Zone Lymphoma
- Interventions
- —
Locations · 50
- Basel, SwitzerlandUniversity Hospital BaselRecruiting at this site
- Bellinzona, SwitzerlandOncology Institute of Southern Switzerland and Institute of Oncology ResearchRecruiting at this site
- Geneva, SwitzerlandHôpitaux Universitaires GenevoisRecruiting at this site
- Sankt Gallen, SwitzerlandKantonsspital St. GallenRecruiting at this site
- Zurich, SwitzerlandUniversity Hospital ZurichRecruiting at this site
- Grenoble, FranceCHU Grenoble AlpesRecruiting at this site
- Toulouse, FranceInstitut Universitaire du Cancer de ToulouseRecruiting at this site
- Alessandria, ItalyAO SS Antonio e Biagio e C. ArrigoRecruiting at this site
- Bari, ItalyIstituto Tumori "Giovanni Paolo II" I.R.C.C.S.Recruiting at this site
- Bergamo, ItalyASST Papa Giovanni XXIIIRecruiting at this site
- Brescia, ItalyASST degli Spedali Civili di BresciaRecruiting at this site
- Catania, ItalyAOU Policlinico Vittorio Emanuele, Presidio FerrarottoRecruiting at this site
- Cona, ItalyAzienda Ospedaliero Universitaria di FerraraRecruiting at this site
- Florence, ItalyAzienda Ospedaliera Universitaria CareggiRecruiting at this site
- Messina, ItalyAzienda Ospedaliera PapardoRecruiting at this site
- Milan, ItalyIRCCS Ospedale San RaffaeleRecruiting at this site
- Milan, ItalyIEO Istituto Europeo di OncologiaRecruiting at this site
- Milan, ItalyASST Grande Ospedale Metropolitano NiguardaRecruiting at this site
- Pescara, ItalyAzienda Sanitaria Locale di PescaraRecruiting at this site
- Aviano, ItalyCentro di Riferimento OncologicoRecruiting at this site
- Pavia, ItalyFondazione IRCCS Policlinico San MatteoRecruiting at this site
- Reggio Emilia, ItalyAUSL IRCCS di Reggio Emilia, Arcispedale S. Maria NuovaRecruiting at this site
- Rome, ItalyFondazione PTV - Policlinico Tor VergataRecruiting at this site
- Rome, ItalySapienza University - AOU Policlinico Umberto IRecruiting at this site
- Rome, ItalyFondazione Policlinico Univeristario A. Gemelli, IRCCS, Università Cattolica S. CuoreRecruiting at this site
- Varese, ItalyASST dei Sette Laghi - Ospedale di Circolo di VareseRecruiting at this site
- Bologna, ItalyIRCCS - Azienda Ospedaliero-Universitaria di BolognaRecruiting at this site
- Naples, ItalyAzienda Ospedaliera Universitaria Federico IIRecruiting at this site
- Novara, ItalyAOU Maggiore della CaritàRecruiting at this site
- Miami, United StatesUniversity of MiamiRecruiting at this site
In total, worldwide, all 50 sites listed in the registry are recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: June 22, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
+ 20 more locations
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.